Drug Type Bispecific antibody |
Synonyms ZG-005, ZG005 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | China | 26 Mar 2025 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 25 Mar 2025 | |
Recurrent Lymphoma | Phase 2 | China | 13 Mar 2025 | |
Refractory Lymphoma | Phase 2 | China | 13 Mar 2025 | |
Advanced biliary tract cancer | Phase 2 | China | 04 Mar 2025 | |
Advanced Hepatocellular Carcinoma | Phase 2 | China | 22 Oct 2024 | |
Advanced Neuroendocrine Carcinoma | Phase 2 | China | 24 May 2024 | |
Advanced Cervical Carcinoma | Phase 2 | China | 18 Mar 2024 | |
Solid tumor | Phase 2 | - | - |
CTR20220021 (NEWS) Manual | Phase 1/2 | 46 | vlglvoyjws(ehvvazgnyw) = oodberevsn etoxxlxjax (pcojcqwwwn ) View more | Positive | 25 Sep 2024 | ||
(20 mg/kg) | vlglvoyjws(ehvvazgnyw) = tpauauaufv etoxxlxjax (pcojcqwwwn ) View more | ||||||
Not Applicable | Advanced Hepatocellular Carcinoma First line | 10 | hakgehmzge(qkmtwqebwy) = tnfketfsgd omhapvljzm (aoogaodadg ) View more | Positive | 25 Sep 2024 | ||
CTR20220021 (ASCO2024) Manual | Phase 1 | 57 | ymkurcawct(phekqumnyk) = eanclhehww ikbokohkwj (nqutdfyjen ) View more | Positive | 24 May 2024 | ||
(cervical cancer) | ymkurcawct(phekqumnyk) = jctrnxksei ikbokohkwj (nqutdfyjen ) View more | ||||||
Phase 1 | 16 | xgezcdbsui(npbmjmwztt) = gxmpwpeihe fsgtllkrsr (omcyqnwmur ) View more | Positive | 26 May 2023 |